Advertisement

Pediatric Rheumatology

, 6:P237 | Cite as

Effective use of rituximab in combination with low dose cyclophosphamide in childhood onset systemic lupus erythematosus (SLE) with relapsing class IV nephritis

  • PM Miettunen
  • LA Hamiwka
  • AW Wade
  • JP Midgley
  • S Grisaru
Open Access
Poster presentation
  • 979 Downloads

Keywords

Systemic Lupus Erythematosus Nephritis Mycophenolate Mofetil Systemic Lupus Erythematosus Activity Renal Flare 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Objectives

We evaluated effectiveness of rituximab, an anti-CD20 monoclonal antibody, in combination with low dose cyclophosphamide and intravenous (IV) methylprednisolone in three pediatric SLE patients with relapsing class IV nephritis.

Methods

Patients 1 and 2

Identical twin females with SLE, complicated by biopsy proven class IV nephritis at age 6-years and treated with NIH cyclophosphamide protocol (NIHCP), had biopsy documented Class IV renal flare at age 10-years; unresponsive to mycophenolate mofetil (MMF) and corticosteroids.

Patient 3

A 12-year old female with SLE, complicated by biopsy documented Class IV nephritis and treated with NIHCP, had 2 further renal flares, which responded to a cumulative dose of 36 grams of cyclophosphamide. At age 16, she had another biopsy documented class IV renal flare, despite maintenance with MMF.

All patients received pulse therapy with: IV cyclophosphamide 0.5 g/m2 with IV methylprednisolone (IVMP) 250 mg on days 1 and 23; IV rituximab 375 mg/m2 on days 2, 9, 16 and 23.

Results

All 3 patients had a dramatic improvement in urine protein-creatinine ratios, and normalization of blood pressure. Despite low-dose daily corticosteroids, all patients had an increase in generalized SLE activity by 4 weeks following rituximab therapy, which responded to re-introduction of MMF. No side effects apart from expected decrease in B-cell counts were noted.

Conclusion

Rituximab in combination with low dose cyclophosphamide and IVMP was effective in controlling recurrent class IV nephritis in 3 pediatric SLE patients.

Re-introduction of mycophenolate mofetil was required within 4 weeks following rituximab therapy to maintain disease remission.

Copyright information

© Miettunen et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • PM Miettunen
    • 1
  • LA Hamiwka
    • 1
  • AW Wade
    • 1
  • JP Midgley
    • 1
  • S Grisaru
    • 1
  1. 1.University of CalgaryCalgaryCanada

Personalised recommendations